Vaccine makers settle France's H1N1 bill

A newspaper has reported that France has struck a deal to pay several large vaccine makers just 16 percent of the amount it had contracted to pay after canceling a huge order of swine flu vaccine. According to Le Figaro, Novartis, GlaxoSmithKline and Sanofi will get €48 million in payment for €358 million of vaccine that the country had ordered and then cancelled. GSK will face the steepest loss from the cancellation. A number of European countries were stuck with large supplies of H1N1 vaccine after the pandemic turned out to be milder than anticipated and a huge portion of their populations shunned the jab. Report

Suggested Articles

GSK has formed several collaborations across the globe that will use its AS03 adjuvant to develop vaccines against the novel coronavirus.

Former FDA Commissioner Scott Gottlieb says 40% of the population needs to be vaccinated to achieve COVID-19 herd immunity.

CanSino Bio, Moderna and a collaboration between Oxford Univeristy and AstraZeneca are frontrunners, but they all face hurdles shared and unique.